A detailed history of Citigroup Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Citigroup Inc holds 60,800 shares of AVXL stock, worth $736,288. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,800
Previous 53,509 13.63%
Holding current value
$736,288
Previous $225,000 53.33%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.11 - $7.04 $29,966 - $51,328
7,291 Added 13.63%
60,800 $345,000
Q2 2024

Aug 12, 2024

SELL
$3.39 - $5.02 $1.76 Million - $2.6 Million
-518,136 Reduced 90.64%
53,509 $225,000
Q1 2024

May 10, 2024

BUY
$4.55 - $6.75 $2.13 Million - $3.17 Million
468,957 Added 456.68%
571,645 $2.91 Million
Q4 2023

Feb 09, 2024

SELL
$5.04 - $9.95 $79,420 - $156,792
-15,758 Reduced 13.3%
102,688 $956,000
Q3 2023

Nov 09, 2023

SELL
$6.55 - $9.37 $36,771 - $52,603
-5,614 Reduced 4.53%
118,446 $775,000
Q2 2023

Aug 10, 2023

SELL
$7.66 - $9.5 $1.94 Million - $2.41 Million
-253,864 Reduced 67.17%
124,060 $1.01 Million
Q1 2023

May 11, 2023

BUY
$8.32 - $11.75 $1.39 Million - $1.96 Million
166,608 Added 78.84%
377,924 $3.24 Million
Q4 2022

Feb 09, 2023

SELL
$7.65 - $14.43 $362,097 - $683,015
-47,333 Reduced 18.3%
211,316 $1.96 Million
Q3 2022

Nov 10, 2022

BUY
$8.9 - $12.86 $678,055 - $979,751
76,186 Added 41.75%
258,649 $2.67 Million
Q2 2022

Aug 10, 2022

BUY
$7.31 - $12.84 $781,197 - $1.37 Million
106,867 Added 141.37%
182,463 $1.83 Million
Q1 2022

May 12, 2022

SELL
$9.74 - $17.69 $1.38 Million - $2.5 Million
-141,353 Reduced 65.15%
75,596 $931,000
Q4 2021

Feb 10, 2022

BUY
$16.88 - $23.31 $998,046 - $1.38 Million
59,126 Added 37.46%
216,949 $3.76 Million
Q3 2021

Nov 10, 2021

BUY
$16.82 - $25.75 $2.65 Million - $4.06 Million
157,823 New
157,823 $2.83 Million

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $944M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.